Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1

Interventions

pembrolizumab 77Nivolumab 65Ipilimumab 41Specimen Handling 34Magnetic Resonance Spectroscopy 27Cyclophosphamide 26Biopsy 20cemiplimab 16fludarabine 14Radiosurgery 14relatlimab 13CTLA-4 Antigen 13binimetinib 12Opdualag 12trametinib 11fludarabine phosphate 11avelumab 9atezolizumab 9Radiotherapy 9Immunoglobulin G 9Blood Specimen Collection 9lifileucel 8dabrafenib 8Disulfides 8encorafenib 7aldesleukin 7X-Rays 7Paclitaxel 7Standard of Care 6Interleukin-2 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epilim × Dermatologic × 90 days × Clear all
NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Thomas Jefferson University

Phase 2 Active not recruiting
210 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡